QuidelOrtho [QDEL] vs Boston Scientific [BSX] Detailed Stock Comparison
QuidelOrtho
NASDAQ
Loading...
Boston Scientific
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: QuidelOrtho wins in 8 metrics, Boston Scientific wins in 10 metrics, with 0 ties. Boston Scientific appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | QuidelOrtho | Boston Scientific | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -0.92 | 57.17 | QuidelOrtho |
| Price-to-Book Ratio | 0.67 | 6.34 | QuidelOrtho |
| Debt-to-Equity Ratio | 100.33 | 53.09 | Boston Scientific |
| PEG Ratio | -0.01 | 0.39 | QuidelOrtho |
| EV/EBITDA | 7.82 | 32.95 | QuidelOrtho |
| Profit Margin (TTM) | -17.01% | 13.55% | Boston Scientific |
| Operating Margin (TTM) | -0.73% | 18.63% | Boston Scientific |
| EBITDA Margin (TTM) | N/A | 18.63% | N/A |
| Return on Equity | -15.64% | 11.55% | Boston Scientific |
| Return on Assets (TTM) | 1.36% | 5.39% | Boston Scientific |
| Free Cash Flow (TTM) | $-112.10M | $2.37B | Boston Scientific |
| 1-Year Return | -32.13% | 11.13% | Boston Scientific |
| Price-to-Sales Ratio (TTM) | 0.69 | 7.69 | QuidelOrtho |
| Enterprise Value | $4.53B | $155.01B | Boston Scientific |
| EV/Revenue Ratio | 1.65 | 8.38 | QuidelOrtho |
| Gross Profit Margin (TTM) | 44.78% | 67.65% | Boston Scientific |
| Revenue per Share (TTM) | $41 | $13 | QuidelOrtho |
| Earnings per Share (Diluted) | $-6.84 | $1.68 | Boston Scientific |
| Beta (Stock Volatility) | 0.27 | 0.61 | QuidelOrtho |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
QuidelOrtho vs Boston Scientific Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| QuidelOrtho | 0.54% | -10.85% | -2.14% | -9.60% | 6.34% | -38.14% |
| Boston Scientific | 0.93% | 0.98% | -10.50% | -5.49% | 6.79% | 8.29% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| QuidelOrtho | -32.13% | -63.48% | -89.09% | 52.16% | 124.86% | 166.35% |
| Boston Scientific | 11.13% | 142.10% | 151.80% | 467.02% | 1,473.82% | 305.66% |
News Based Sentiment: QuidelOrtho vs Boston Scientific
QuidelOrtho
News based Sentiment: MIXED
October presented a complex picture for QuidelOrtho, with positive industry tailwinds offset by analyst downgrades, increased debt costs, and concerns about revenue exposure to China. While the company is focused on improving efficiency and launching new products, the overall narrative is one of significant challenges and uncertainties, making it a mixed investment story.
Boston Scientific
News based Sentiment: POSITIVE
October was a largely positive month for Boston Scientific, highlighted by strong Q2 earnings, strategic acquisitions like Elutia, and continued positive analyst sentiment. While insider selling is a concern, the overall narrative points to a company well-positioned for future growth and market leadership, making it a significant month for investors.
Performance & Financial Health Analysis: QuidelOrtho vs Boston Scientific
| Metric | QDEL | BSX |
|---|---|---|
| Market Information | ||
| Market Cap | $1.89B | $142.10B |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 1,487,820 | 11,082,776 |
| 90 Day Avg. Volume | 1,319,670 | 10,001,415 |
| Last Close | $27.86 | $96.79 |
| 52 Week Range | $22.05 - $49.45 | $80.64 - $109.50 |
| % from 52W High | -43.66% | -11.61% |
| All-Time High | $306.72 (Aug 03, 2020) | $109.50 (Sep 09, 2025) |
| % from All-Time High | -90.92% | -11.61% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.04% | 0.23% |
| Quarterly Earnings Growth | -0.04% | 1.46% |
| Financial Health | ||
| Profit Margin (TTM) | -0.17% | 0.14% |
| Operating Margin (TTM) | -0.01% | 0.19% |
| Return on Equity (TTM) | -0.16% | 0.12% |
| Debt to Equity (MRQ) | 100.33 | 53.09 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $41.25 | $15.14 |
| Cash per Share (MRQ) | $2.25 | $0.36 |
| Operating Cash Flow (TTM) | $200.40M | $4.28B |
| Levered Free Cash Flow (TTM) | $410.38M | $2.94B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: QuidelOrtho vs Boston Scientific
| Metric | QDEL | BSX |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -0.92 | 57.17 |
| Forward P/E | 10.45 | 34.42 |
| PEG Ratio | -0.01 | 0.39 |
| Price to Sales (TTM) | 0.69 | 7.69 |
| Price to Book (MRQ) | 0.67 | 6.34 |
| Market Capitalization | ||
| Market Capitalization | $1.89B | $142.10B |
| Enterprise Value | $4.53B | $155.01B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.65 | 8.38 |
| Enterprise to EBITDA | 7.82 | 32.95 |
| Risk & Other Metrics | ||
| Beta | 0.27 | 0.61 |
| Book Value per Share (MRQ) | $41.25 | $15.14 |
Financial Statements Comparison: QuidelOrtho vs Boston Scientific
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | QDEL | BSX |
|---|---|---|
| Revenue/Sales | $613.90M | $4.66B |
| Cost of Goods Sold | $339.00M | $1.45B |
| Gross Profit | $274.90M | $3.21B |
| Research & Development | $45.70M | $443.00M |
| Operating Income (EBIT) | $-1.80M | $937.00M |
| EBITDA | $100.00M | $1.23B |
| Pre-Tax Income | $-229.60M | $805.00M |
| Income Tax | $25.80M | $133.00M |
| Net Income (Profit) | $-255.40M | $672.00M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | QDEL | BSX |
|---|---|---|
| Cash & Equivalents | $127.10M | $725.00M |
| Total Current Assets | $1.26B | $7.34B |
| Total Current Liabilities | $1.05B | $5.06B |
| Long-Term Debt | $2.27B | $10.93B |
| Total Shareholders Equity | $3.00B | $22.45B |
| Retained Earnings | $123.10M | $3.35B |
| Property, Plant & Equipment | $2.35B | $448.00M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | QDEL | BSX |
|---|---|---|
| Operating Cash Flow | $41.90M | $513.00M |
| Capital Expenditures | $-56.20M | $-187.00M |
| Free Cash Flow | $9.40M | $277.00M |
| Debt Repayment | $-36.00M | $-1.31B |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | QDEL | BSX |
|---|---|---|
| Shares Short | 8.15M | 19.02M |
| Short Ratio | 7.03 | 2.76 |
| Short % of Float | 0.20% | 0.01% |
| Average Daily Volume (10 Day) | 1,487,820 | 11,082,776 |
| Average Daily Volume (90 Day) | 1,319,670 | 10,001,415 |
| Shares Outstanding | 67.26M | 1.47B |
| Float Shares | 62.65M | 1.48B |
| % Held by Insiders | 0.01% | 0.00% |
| % Held by Institutions | 1.17% | 0.94% |
Dividend Analysis & Yield Comparison: QuidelOrtho vs Boston Scientific
| Metric | QDEL | BSX |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |